Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)的首席医疗官Dan Karlin最近出售了公司6,643股普通股。该公司是一家市值5.02亿美元的生物科技公司，其股票在过去一年中上涨超过100%。根据 InvestingPro 的数据，分析师对MNMD保持看好态度，多项关键指标显示公司财务状况良好。这次出售是在2024年12月26日执行的，属于根据规则10b5- ...

在其他最近的新闻中，生物制药公司Mind Medicine (MindMed)有了重大进展。该公司用于治疗广泛性焦虑障碍的实验性治疗MM120 ODT获得了英国药品和保健品监管局的创新通行证。MindMed还进行了关键的高管任命，欢迎Javier A. Muniz博士担任研发战略副总裁，Gregg A. Pratt博士担任首席监管和质量保证官。

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Mind Medicine (MNMD) announced that it will be added to the Nasdaq Biotechnology Index NBI , effective at market open on Monday, December 23. “2024 has been a transformational year for MindMed.

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Get Free Report) shares were down 8.5% on Friday following insider selling activity. The company traded as low as $6.98 and last traded at $6.98.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Inc. (NASDAQ:MNMD – Get Free Report) shares gapped down before the market opened on Thursday . The stock had previously closed at $7.32, but opened at $7.15. Mind Medicine (MindMed) shares last traded ...

Shares of Clearmind Medicine more than doubled after the Institutional Review Board approved a clinical trial of its flagship compound as a treatment for alcohol use disorder. The stock was changing ...

Biotech company Clearmind Medicine (CMND) has received the approval of the Institutional Review Board for its Phase I/IIa clinical trial of CMND-100, targeting alcohol use disorder.

Scientists just discovered that a common cat parasite might be the key to treating brain disorders. Here's how this weird breakthrough could change ev ...